EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application dorzolamide HCl and timolol maleate ophthalmic solution, 2% / 0.5%. Aurobindo Pharma’s dorzolamide HCl and timolol maleate ophthalmic solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Cosopt Ophthalmic Solution, 2% / 0.5% marketed by Akorn Operating Company LLC.

Dorzolamide HCl and timolol maleate ophthalmic solution, is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers

Dorzolamide HCl and timolol maleate ophthalmic solution has an estimated market size of U.S. $70 Million for the twelve months ending March 2021, as per IQVIA.